Agios drug improves progression-free survival in Phase III cholangiocarcinoma study
The company announced the presentation of data at the ESMO meeting in Barcelona for Tibsovo, in patients with IDH1-mutant bile duct cancer. The drug is approved for treating IDH1-mutation positive acute myeloid leukemia.